Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine. [electronic resource]
Producer: 20061212Description: 807-13 p. digitalISSN:- 0959-4973
- Antimetabolites, Antineoplastic -- therapeutic use
- Antineoplastic Agents, Hormonal -- therapeutic use
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Cell Line, Tumor
- Cell Size
- Cell Survival -- drug effects
- Docetaxel
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Drug Synergism
- Erlotinib Hydrochloride
- Floxuridine -- therapeutic use
- Humans
- Male
- Prostatic Neoplasms -- drug therapy
- Quinazolines -- therapeutic use
- Taxoids -- therapeutic use
- Thymidine Phosphorylase -- metabolism
- Thymidylate Synthase -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.